Investigator-Initiated Studies

We’re committed to supporting investigator-initiated research that promotes the advancement of medical and scientific knowledge involving AbbVie’s products and therapeutic areas of interest.

Advancing Science through Investigator-led Research

The research from investigator-initiated studies may expand our understanding of our products and their potential applications. Plus, it may improve patient care and spark new ideas for further disease-related research.

The AbbVie IIS Program provides an opportunity to academic and community-based physicians and researchers worldwide interested in conducting their own research to apply for research support.

Visit the IIS Submission Portal to learn more or to apply.

How to apply

If you’re an investigator, you can initiate the application process by submitting a brief summary of the proposed research to AbbVie through our IIS Portal. IIS applications are accepted on a rolling submission basis.

After you apply

Following the review of the initial submission, you may be asked to submit a full protocol and final study budget for further evaluation. We hold protocol review meetings monthly. Submission of a proposal does not imply or guarantee approval. The committee evaluates proposals according to their scientific merit, alignment with our areas of research interest and available funding. Financial and/or product support is contingent upon full execution of the research agreement by both parties.

Therapeutic Areas of Interest

  • Glecaprevir/Pibrentasvir

Dermatology

  • HUMIRA (adalimumab)

Gastroenterology

  • HUMIRA (adalimumab)

Rheumatology

  • HUMIRA (adalimumab)

Ophthalmology

  • HUMIRA (adalimumab)
  • Duodopa/Duopa (levodopa/carbidopa intestinal gel): Submissions should be limited to funding-only requests as product will not be provided.
  • Daclizumab: Disease State Only. Support in the form of product will not be accepted for consideration.
  • Venetoclax (ABT-199)
  • Navitoclax (ABT-263)
  • Veliparib (ABT-888)
  • ABT-414 and ABT-806
  • Rovalpituzumab Tesirine (Rova-T)
  • Creon (pancrelipase)
  • Atrasentan: Accepting proposals requesting funding support only for disease state research in diabetic kidney disease. Support in the form of product will not be accepted for consideration.
  • Lupron: Benign gynecologic diseases, including endometriosis and uterine fibroids only. Product requests will be considered based on available resources.
  • Elagolix: Benign gynecologic diseases, including endometriosis and uterine fibroids only. Support in the form of product will not be accepted for consideration.